Goncalves da Costa S, Santos E B, Lagrange P H
Départemento de Protozoologia, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.
Ann Inst Pasteur Immunol. 1988 Mar-Apr;139(2):143-56. doi: 10.1016/0769-2625(88)90036-0.
Attempts to develop a satisfactory vaccine against New World cutaneous leishmaniasis have been made with varying success. We found that in mice, pretreated subcutaneously with 2 X 10(6) BCG organisms 2 weeks prior to immunization at the same site with as low as 10 micrograms of a microsomal preparation (Pol-F) of Leishmania mexicana amazonensis, a profound alteration was observed in the course of infection produced by inoculation of virulent amastigotes of the same strain. The BCG-Pol-F vaccine preparation was consistently shown to have a protective capacity associated with larger classical cellular immune response (skin test) and higher specific antibody titres in response to leishmanial challenge dose (1 X 10(6) amastigotes/mouse).
人们曾尝试研发一种针对新大陆皮肤利什曼病的有效疫苗，但成效各异。我们发现，在小鼠于同一部位皮下预先接种2×10⁶ 个卡介苗生物体两周后，再用低至10微克亚马逊利什曼原虫的微粒体制剂（Pol-F）进行免疫接种，在接种同一菌株的强毒无鞭毛体所引发的感染过程中观察到了显著变化。卡介苗 - Pol-F疫苗制剂始终显示出具有保护能力，这与更大的经典细胞免疫反应（皮肤试验）以及针对利什曼原虫攻击剂量（1×10⁶ 个无鞭毛体/小鼠）产生的更高特异性抗体滴度相关。
